A Phase 1b/2 Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Study of BXCL501 to Treat Symptoms of Acute Opioid Withdrawal in Patients With Opioid Use Disorder Who Are Physically Dependent on Opioids
Latest Information Update: 08 Sep 2023
At a glance
- Drugs Dexmedetomidine (Primary)
- Indications Opioid-related disorders
- Focus Adverse reactions; Proof of concept
- Acronyms RELEASE
- Sponsors BioXcel Therapeutics
Most Recent Events
- 31 Mar 2021 Status changed from recruiting to completed according to a BioXcel Therapeutics media release.
- 31 Mar 2021 Results presented in BioXcel Therapeutics media release.
- 11 Mar 2021 According to a BioXcel Therapeutics media release, topline readout expected this month